Derma Sciences (DSCI) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Piper Jaffray Cuts Price Target on Derma Sciences (DSCI) Following Mixed 3Q Results
November 10, 2015 9:33 AM ESTPiper Jaffray reiterated a Neutral rating on Derma Sciences (NASDAQ: DSCI), and cut the price target to $6.00 (from $7.00), following the company's 3Q earnings report. Derma Sciences reported net earnings per share of ($0.35), beating consensus of ($0.43), on revenues of $22M (vs. Street's 22.31M).
Analyst David Amsellem... More
